Search Result

Results for "

thrombin-induced aggregation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Bacterial (1) Drug Metabolite (2) Factor Xa (1) FAP (1) Integrin (1) Isotope-Labeled Compounds (3) JNK (2) NOD-like Receptor (NLR) (1) PANoptosis (1) Phosphatase (1) Phosphodiesterase (PDE) (4) Protease Activated Receptor (PAR) (7) Reference Standards (2) Src (1) Syk (1) Thrombin (10)
By Research Areas:	Cancer (5) Cardiovascular Disease (23) Endocrinology (2) Infection (1) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10163

Dabigatran Maximum Cited Publications 6 Publications Verification BIBR 953; BIBR 953ZW	Thrombin	Cardiovascular Disease Cancer
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct *thrombin* inhibitor (K_i=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-14993

SCH79797 5 Publications Verification	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .

HY-14994

SCH79797 dihydrochloride 5 Publications Verification	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .

HY-78263

MNS 3 Publications Verification NSC 170724; 5-(2-Nitrovinyl)benzodioxole	Src Syk NOD-like Receptor (NLR) Integrin PANoptosis	Neurological Disease Inflammation/Immunology Cancer
MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC₅₀ of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC₅₀ values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells .

HY-P1488

Bradykinin (1-5)	Drug Metabolite	Cardiovascular Disease
Bradykinin (1-5) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE) . Bradykinin (1-5) inhibits α- and γ-thrombin-induced platelet aggregation .

HY-108419

WHI-P258	JNK	Cancer
WHI-P258, a quinazoline compound, binds to the active site of JAK3 with an estimated K_i of 72 µM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM .

HY-10163S

Dabigatran-d4 BIBR 953-d₄; BIBR 953ZW-d₄	Isotope-Labeled Compounds Thrombin	Cardiovascular Disease
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-162558

NCGC00351170	Factor Xa	Cardiovascular Disease
NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-α_IIbβ₃ interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation .

HY-10163S1

Dabigatran-d3 BIBR 953-d₃; BIBR 953ZW-d₃	Thrombin	Cardiovascular Disease
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163R

Dabigatran (Standard) BIBR 953 (Standard); BIBR 953ZW (Standard)	Reference Standards Thrombin	Cardiovascular Disease Cancer
Dabigatran (Standard) is the analytical standard of Dabigatran. This product is intended for research and analytical applications. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) .

HY-165436

Toborinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Toborinone is an inotropic agent. Toborinone increases cAMP and intracellular calcium levels through inhibiting PDE. Toborinone inhibits thrombin-induced platelet aggregation with an IC₅₀ of 9.7 μM .

HY-N10271

SCH 38519	Bacterial	Infection
SCH 38519 is a platelet aggregation inhibitor. SCH 38519 inhibits thrombin-induced aggregation of human platelets with an IC₅₀ of 68 μg/mL. SCH 38519 is also active against Gram-positive and Gram-negative bacteria .

HY-117561

DuP 714	Thrombin	Cardiovascular Disease
DuP 714 is an oral active *thrombin* inhibitor with the IC₅₀ values of 150 nM aganist thrombin-induced aggregation in washed human platelets. DuP 714 can be used for study of arterial thrombosi .

HY-112631

OPC 33540	Phosphodiesterase (PDE)	Cardiovascular Disease
OPC-33540 is a highly selective and competitive PDE3 inhibitor with IC₅₀ values of 0.32 nM (PDE3A) and 1.5 nM (PDE3B). OPC-33540 exhibits IC₅₀s against PDE1, PDE2, PDE4, PDE5, and PDE7 of 42.9, 52.3, 100.8, 2.5, and 51.3 μM, respectively. OPC-33540 significantly enhances cAMP accumulation in platelets and effectively inhibits thrombin-induced platelet aggregation. OPC-33540 can be used in antithrombotic studies .

HY-14993R

SCH79797 (Standard)	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 (Standard) is the analytical standard of SCH79797. This product is intended for research and analytical applications. SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .

HY-128345

UDM-001651	Protease Activated Receptor (PAR)	Cardiovascular Disease
UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC₅₀=4 nM; K_d=1.4 nM). UDM-001651 shows antiplatelet potency (IC₅₀=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP) .

HY-161867

Platelet aggregation-IN-1	Thrombin	Others
Platelet aggregation-IN-1 (Compound 10e) is an inhibitor for platelet aggregation, that inhibits 100% thrombin-induced platalet aggregation at 50 μM .

HY-108555

FR-171113	Protease Activated Receptor (PAR)	Cardiovascular Disease
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 0.29 μM. .

HY-10163S2

Dabigatran-13C6 BIBR 953-¹³C₆; BIBR 953ZW-¹³C₆	Thrombin	Cardiovascular Disease
Dabigatran- ¹³C₆ is the ¹³C labeled Dabigatran . Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S3

Dabigatran-13C,d3 BIBR 953-¹³C,d₃; BIBR 953ZW-¹³C,d₃	Isotope-Labeled Compounds Thrombin	Cardiovascular Disease
Dabigatran- ¹³C,d₃ is the ¹³C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S5

Dabigatran-d7 BIBR 953-d₇; BIBR 953ZW-d₇	Isotope-Labeled Compounds Thrombin	Cardiovascular Disease
Dabigatran-d₇ (BIBR 953-d₇; BIBR 953ZW-d₇) is the deuterium labeled Dabigatran (HY-10163). Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-19674

SSR182289 SSR182289A free base	Thrombin	Cardiovascular Disease
SSR182289 (SSR182289A free base) is a selective and potent orally active *thrombin* inhibitor. SSR182289 competitively and selectivity inhibits human thrombin (K_i=0.031 μM). SSR182289 demonstrates anticoagulant activity in vitro (thrombin time EC₁₀₀=96 nM) and inhibits tissue factor-induced thrombin generation (IC₅₀=0.15 μM) in human plasma. SSR182289 inhibits thrombin-induced aggregation of human platelets (IC₅₀=32 nM), but has no effect on aggregation induced by other platelet agonists .

HY-14994R

SCH79797 dihydrochloride (Standard)	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 (dihydrochloride) (Standard) is the analytical standard of SCH79797 (dihydrochloride). This product is intended for research and analytical applications. SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .

HY-108419R

WHI-P258 (Standard)	Reference Standards JNK	Cancer
WHI-P258 (Standard) is the analytical standard of WHI-P258 (HY-108419). This product is intended for research and analytical applications. WHI-P258, a quinazoline compound, binds to the active site of JAK3 with an estimated K_i of 72 µM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM .

HY-105931

Lixazinone RS-82856	Phosphodiesterase (PDE)	Cardiovascular Disease Endocrinology
Lixazinone (RS-82856) is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC₅₀ value of 22 nM. Lixazinone exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [ ³²P]cGMP. Lixazinone can be used in the research of polycystic kidney disease and congestive heart failure .

HY-113822

Lixazinone hydrogensulfate RS-82856 hydrogensulfate	Phosphodiesterase (PDE)	Cardiovascular Disease Endocrinology
Lixazinone (RS-82856) hydrogensulfate is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC₅₀ value of 22 nM. Lixazinone hydrogensulfate exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone hydrogensulfate increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [ ³²P]cGMP. Lixazinone hydrogensulfate can be used in the research of polycystic kidney disease and congestive heart failure .

HY-182434

CL 118326	Phosphatase FAP	Inflammation/Immunology
CL 118326 is a potent, selective, competitive inhibitor of mammalian pancreatic phospholipase A₂ (PLA₂) and a weak antagonist of platelet-activating factor receptor (PAF receptor). CL 118326 competitively inhibits mammalian pancreatic PLA₂ (porcine: IC₅₀ = 1.55 μg/mL), and shows no activity against snake venom or bee venom PLA₂. CL 118326 inhibits PAF-induced and thrombin-induced platelet aggregation, as well as the release of leukotriene (LTC₄) and histamine from basophil-enriched leukocytes. CL 118326 can be used for research on inflammation and allergic reactions .

HY-182573

RWJ-58259	Protease Activated Receptor (PAR)	Cardiovascular Disease
RWJ-58259 is a selective PAR-1 inhibitor with an IC₅₀ value of 0.15 μM. RWJ-58259 binds selectively to PAR-1, blocks the binding of tethered ligands, interferes with calcium mobilization and PAR-1-related cellular functions, and exhibits no PAR-1 agonist activity or thrombin proteolytic inhibitory activity. RWJ-58259 inhibits thrombin-induced platelet aggregation, calcium signaling and vascular smooth muscle cell proliferation, reduces neointimal thickness and arterial stenosis, and alleviates vascular occlusion and platelet deposition. RWJ-58259 can be used in the research of thrombotic diseases and vascular injury associated with acute coronary intervention .

HY-P1488A

Bradykinin (1-5) TFA	Drug Metabolite	Cardiovascular Disease
Bradykinin (1-5) (TFA) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE). Bradykinin (1-5) (TFA) inhibits α- and γ-thrombin-induced platelet aggregation .

Cat. No.	Product Name	Target	Research Area

HY-P1488

Bradykinin (1-5)	Drug Metabolite	Cardiovascular Disease
Bradykinin (1-5) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE) . Bradykinin (1-5) inhibits α- and γ-thrombin-induced platelet aggregation .

HY-P1488A

Bradykinin (1-5) TFA	Drug Metabolite	Cardiovascular Disease
Bradykinin (1-5) (TFA) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE). Bradykinin (1-5) (TFA) inhibits α- and γ-thrombin-induced platelet aggregation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10271

SCH 38519	Infection Quinones Monophenols Microorganisms Classification of Application Fields Anthraquinones Phenols Disease Research Fields Source Classification	Bacterial
SCH 38519 is a platelet aggregation inhibitor. SCH 38519 inhibits thrombin-induced aggregation of human platelets with an IC₅₀ of 68 μg/mL. SCH 38519 is also active against Gram-positive and Gram-negative bacteria .

Cat. No.	Product Name	Chemical Structure

HY-10163S

Dabigatran-d4
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S1

Dabigatran-d3
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S2

Dabigatran-13C6
Dabigatran- ¹³C₆ is the ¹³C labeled Dabigatran . Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S3

Dabigatran-13C,d3
Dabigatran- ¹³C,d₃ is the ¹³C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S5

Dabigatran-d7
Dabigatran-d₇ (BIBR 953-d₇; BIBR 953ZW-d₇) is the deuterium labeled Dabigatran (HY-10163). Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

thrombin-induced aggregation

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products